Therapies targeting essential survival pathways in glioblastoma [e.g., inhibitors of receptor tyrosine kinases (RTKs) or signaling molecules] have achieved modest, yet encouraging, therapeutic benefits in recurrent glioblastoma (11–22). The gene discussed is NTRK1; the disease is glioblastoma.